Core Viewpoint - The company has completed the repurchase and cancellation of shares, reducing its total share capital and enhancing shareholder value through improved earnings per share [2][8][12]. Group 1: Share Repurchase Details - The company repurchased a total of 19,304,400 shares, which accounts for 0.8540% of the total share capital prior to the cancellation [2][6]. - Following the cancellation, the total share capital decreased from 2,260,382,715 shares to 2,241,078,315 shares [2][9]. - The repurchase was conducted using self-owned funds and a special loan for stock repurchase, with a total expenditure between RMB 100 million and RMB 150 million, and a maximum repurchase price of RMB 9.16 per share [3][4]. Group 2: Implementation and Compliance - The repurchase was executed from May 27, 2024, to May 9, 2025, with a total transaction amount of RMB 100,019,214.1, excluding transaction fees [6]. - The company adhered to the regulations set forth by the Shenzhen Stock Exchange regarding share repurchase disclosures, providing monthly updates on the progress [5]. Group 3: Impact of Share Cancellation - The cancellation of shares is expected to enhance earnings per share and improve returns for shareholders without significantly affecting the company's financial, operational, or debt servicing capabilities [8]. - The shareholding structure remains compliant with listing requirements, and there will be no change in control of the company as a result of this transaction [8][13]. Group 4: Future Arrangements - The company will proceed with necessary legal and regulatory filings following the completion of the share cancellation [10].

证券代码：000516 证券简称：国际医学 公告编号：2025-027 西安国际医学投资股份有限公司 关于控股股东及其一致行动人持股比例被动增加 触及1%整数倍的公告 2 4．承诺、计划等履行情况 本次变动是否为履 行已作出的承诺、 意向、计划 是□ 否☑ 如是，请说明承诺、意向、计划的具体情况及履行进度。 本次变动是否存在 违反《证券法》《上 市公司收购管理办 法》等法律、行政 法规、部门规章、 规范性文件和本所 业务规则等规定的 情况 是□ 否☑ 如是，请说明违规的具体情况、整改计划和处理措施。 5．被限制表决权的股份情况 按照《证券法》第 六十三条的规定， 是否存在不得行使 表决权的股份 是□ 否☑ 如是，请说明对应股份数量占现有上市公司股本的比例。 6．30%以上股东增持股份的说明（不适用） 7．备查文件 1．中国证券登记结算有限责任公司持股变动明细 ☑ 2．相关书面承诺文件 □ 3．律师的书面意见 □ 4．深交所要求的其他文件 ☑ 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"公司"）已于2025年 5月28 ...

特别提示： 1、西安国际医学投资股份有限公司（以下简称"公司"）本次注 销的股份数量为19,304,400股，占公司本次注销前总股本的0.8540%。 本次回购股份注销完成后，公司总股本由现在的2,260,382,715股变更 为2,241,078,315股。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司 本次回购股份注销事宜已于2025年5月28日办理完成。 证券代码：000516 证券简称：国际医学 公告编号：2025-026 西安国际医学投资股份有限公司 关于回购股份注销完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"本公司"或"公司"） 于2024年4月24日召开第十二届董事会第十五次会议，并于2024年5月20 日召开2023年度股东大会，审议通过了《关于回购公司股份方案的议案》 及《关于提请股东大会授权董事会办理本次回购相关事宜的议案》，决 定使用自有资金以集中竞价交易方式回购已发行的人民币普通股（A股） 股票，回购的股份将全部用于注销以减少公司注册资本。本次回购的资 金总 ...

Core Points - The opening of the "Haikou-Tbilisi-Tel Aviv" cargo route enhances the international air cargo network of Hainan Free Trade Port [3] - The route is operated by Georgian Airways, with one flight per week, primarily focusing on e-commerce and general cargo [3] - The establishment of a tripartite communication and cooperation mechanism ensures efficient operation and support for the new route [3] - The route leverages the sixth freedom rights to connect the cargo markets of China, Georgia, and Israel, facilitating cross-border trade and supply chain optimization [3] - Haikou Meilan International Airport has already launched two international cargo routes this year, connecting three international cargo destinations [8] - The airport aims to become a regional air transport hub, enhancing the efficiency of international logistics channels and developing a multi-layered international air logistics ecosystem [8]

Group 1 - The company has experienced a significant slowdown in service volume and revenue growth, with the current capacity indicators such as hospital beds nearing saturation [1] - The net profit of the three main subsidiaries disclosed in the 2024 annual report totals nearly 500 million, while the consolidated report shows a loss of over 200 million, raising questions about the accounting factors that led to a loss of over 700 million in profit [1] - The company indicates that there is still room for growth in bed usage, despite the current utilization rate of approximately 3,300-3,600 beds out of a planned 8,637 [1] Group 2 - The company plans to leverage its existing resources, including a tertiary hospital and JCI certification, to provide a comprehensive healthcare service platform, focusing on high-quality medical services and specialized care [2] - Future business expansion will include life health management, integrated medical care, internet healthcare services, international medical services, smart hospitals, and digital healthcare [2] - The company aims to establish itself as a leading healthcare service group in the industry by enhancing its core medical services and developing innovative operational models [2]

Group 1 - International Medical's stock closed at 5.13 yuan on May 23, 2025, down 0.77% from 5.17 yuan the previous week, with a market cap of 11.596 billion yuan, ranking 13th in the medical services sector and 1318th in the A-share market [1] - The company announced a share buyback plan with a total fund of 100 million to 150 million yuan, with a maximum buyback price of 9.16 yuan per share, and a duration of 12 months [2] - As of May 20, 2025, the company had repurchased 19,304,400 shares, accounting for 0.8540% of the total share capital, with a total transaction amount of approximately 100 million yuan [2] Group 2 - The controlling shareholder, Century Xinyuan, has engaged in a stock pledge repurchase transaction, with 50 million shares postponed for repurchase until May 21, 2026, and 2 million shares released from pledge [3] - Century Xinyuan holds 616,061,198 shares, representing 27.25% of the total share capital, with 429,860,000 shares pledged, accounting for 69.78% of its holdings and 19.02% of the total share capital [3] - The company board will continue to monitor the stock pledge situation of Century Xinyuan and ensure timely information disclosure [3]

证券代码：000516 证券简称：国际医学 公告编号：2025-025 西安国际医学投资股份有限公司 关于控股股东进行股票质押式回购交易的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"公司"）近日接到控 股股东陕西世纪新元商业管理有限公司（以下简称"世纪新元"）的通 知，世纪新元使用其持有的本公司部分股份与国都证券股份有限公司进 行的股票质押式回购交易已于近期办理了部分解除质押和延期购回，具 体事项如下： 二、控股股东股份部分解除质押的基本情况 | 股东 | 是否为控股股东 | 本次解除质押 | 占其所 | 占公司 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 或第一大股东及 | 股份数量（股） | 持股份 | 总股本 | 起始日 | 解除日期 | 质权人 | | | 其一致行动人 | | 比例 | 比例 | | | | | 世纪 | | | | | 2023 年 5 | 2025 年 5 | 国都证券股份有限公 | | 新元 ...

Core Viewpoint - International Medical (000516) is experiencing growth in business scale and revenue, but is still facing losses due to the operational costs of newly established medical projects [1][2]. Group 1: Financial Performance - As of May 21, 2025, International Medical's stock closed at 5.23 yuan, up 0.77%, with a trading volume of 207,800 shares and a turnover of 109 million yuan [1]. - The company's revenue increased from 2.711 billion yuan in 2022 to 4.815 billion yuan in 2024, while the net profit attributable to the parent company improved from a loss of 1.177 billion yuan to a loss of 254 million yuan over the same period [1]. - The number of outpatient and emergency service visits rose from 1.5467 million in 2022 to 2.5727 million in 2024, and the total number of employees increased from 7,750 to 8,858 [1]. Group 2: Stock Buyback and Management Actions - On April 24, 2024, the company announced a stock buyback plan with a total fund of no less than 100 million yuan and no more than 150 million yuan, with a maximum buyback price of 9.16 yuan per share [2]. - As of May 20, 2025, the company had repurchased 19,304,400 shares, accounting for 0.854% of the total share capital, with a total transaction amount of approximately 100 million yuan [3]. - The company’s board and president, Liu Ruixuan, increased their holdings by purchasing 100,000 shares on September 2, 2024 [2].

证券代码：000516 证券简称：国际医学 公告编号：2025-024 西安国际医学投资股份有限公司 关于股份回购实施结果暨股份变动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"本公司"或"公司"） 于2024年4月24日召开第十二届董事会第十五次会议，并于2024年5月20 日召开2023年度股东大会，审议通过了《关于回购公司股份方案的议案》 及《关于提请股东大会授权董事会办理本次回购相关事宜的议案》，决 定使用自有资金以集中竞价交易方式回购已发行的人民币普通股（A股） 股票，回购的股份将全部用于注销以减少公司注册资本。本次回购的资 金总额不低于人民币10,000万元（含）且不超过人民币15,000万元（含）， 回购价格不超过人民币9.16元/股（含），具体回购股份的数量以回购 结束时实际回购的股份数量为准。回购期限为自公司股东大会审议通过 本次回购方案之日起12个月内。公司已在中国证券登记结算有限责任公 司深圳分公司开立股份回购专用证券账户。具体内容详见公司分别于 2024年4月26日和5月21日在《中国证券 ...

Core Viewpoint - The Guangxi Zhuang Autonomous Region's Finance Department has significantly increased financial support for the Fangchenggang International Medical Open Experimental Zone, raising a total of 41.22 billion RMB since 2019 to enhance infrastructure and promote high-quality industrial development in the region [1][2] Group 1: Financial Support and Infrastructure Development - The Finance Department has allocated a total of 25.37 billion RMB to support various projects, including the construction of infrastructure for the non-human primate conservation base [1] - The financial support has effectively promoted the construction of infrastructure and improved the comprehensive carrying capacity of the experimental zone, facilitating the accelerated gathering of three main industries: breeding of experimental animals, preclinical drug research, and traditional medicine development [1] - As of April 2025, the experimental zone has registered 264 enterprises, including 23 high-tech enterprises and 50 recognized technology-based small and medium-sized enterprises [1] Group 2: Healthcare and Medical Services - The Finance Department has also allocated 13.55 billion RMB to support major healthcare projects, including the construction of a major epidemic treatment base and the relocation of the disease prevention and control center in Fangchenggang [1] - The collaboration between Guangxi People's Hospital and Fangchenggang First People's Hospital aims to establish the first regional medical center in the autonomous region, focusing on six key specialties, including cardiology [2] - The number of hospital beds per thousand people in Fangchenggang has increased from 4.23 in 2019 to 5.42 in 2024, indicating an expansion of quality medical resources [2] Group 3: Research and Innovation - A total of 2.3 billion RMB has been allocated to support the construction of a food safety and nutrition innovation platform and various research projects related to non-human primates, medical service models, drug treatment, and smart medicine [2] - The experimental zone has achieved breakthroughs in innovation and research, including the creation of the world's first non-alcoholic fatty liver disease model using non-human primates [2] - The Guangxi Luhang Biopharmaceutical Technology Co., Ltd. has received clinical approval for its targeted drugs AHT-101 and AHT-102 for gastric and pancreatic cancer [2]